The cloudy crystal ball of cost-effectiveness studies

Value in Health

Volumn 16, Issue 6, 2013, Pages 1100-1102

  Frederix, Gerardus W J ^a   Severens, Johan L ^c   Hövels, Anke M ^a   Raaijmakers, Jan A M ^a,d   Schellens, Jan H M ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d Glaxo SmithKline   (Netherlands)

Author keywords

cancer cost effectiveness decision making standardization

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; STANDARDIZATION;

CANCER; COST-EFFECTIVENESS; DECISION MAKING; STANDARDIZATION;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MODELS, ECONOMETRIC; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS;

EID: 84884268842     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.06.012     Document Type: Review

References (5)

1. M.J. Buxton, M.F. Drummond, and B.A. Van Hout Modelling in economic evaluation: an unavoidable fact of life Health Econ 6 1997 217 227
2. M. Baum, A.U. Budzar, and J. Cuzick Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
3. G.W. Frederix, J.L. Severens, and A.M. Hovels Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes Value Health 15 2012 94 105
4. M. Drummond, M. Barbieri, and J. Cook Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report Value Health 12 2009 409 418
5. R. Goeree, J. He, and D. O'Reilly Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application Clinicoecon Outcomes Res 3 2011 89 104